IMMUNOHISTOCHEMICAL EXPRESSION OF GLUT-1 IN EPITHELIAL OVARIAN TUMORS: CORRELATION WITH THE CLINICOPATHOLOGICAL FACTORS AND TUMOR PROLIFERATIVE MARKER PCNA.

* Samah S. Elbasateeny 1 , Mai M. Abdelwahab 1 , Mohamed A.Ibrahem 2 and Ibtsam S. Harera 3 . 1. Pathology Department, Faculty of medicine, Zagazig University, Egypt. 2. Obstetrics and Gynecology Department, Faculty of medicine, Zagazig University, Egypt. 3. Surgery Department, Faculty of medicine, Zagazig University, Egypt. ...................................................................................................................... Manuscript Info Abstract ......................... ........................................................................ Manuscript History

[1]  S. Hauptmann,et al.  The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications , 2016, Archives of Gynecology and Obstetrics.

[2]  T. Seidal,et al.  The relationship of the angiogenesis regulators VEGF-A, VEGF-R1 and VEGF-R2 to p53 status and prognostic factors in epithelial ovarian carcinoma in FIGO-stages I–II , 2016, International journal of oncology.

[3]  Li Lin,et al.  Clinical significance of COX-2, GLUT-1 and VEGF expressions in endometrial cancer tissues , 2015, Pakistan journal of medical sciences.

[4]  N. Mikhail,et al.  Cancer Incidence in Egypt: Results of the National Population-Based Cancer Registry Program , 2014, Journal of cancer epidemiology.

[5]  Yu Cai,et al.  Expression of glucose transporter protein 1 and p63 in serous ovarian tumor , 2014, The journal of obstetrics and gynaecology research.

[6]  Hai-gang Li,et al.  Expression of CD44v3, Erythropoietin and VEGF-C in Gastric Adenocarcinomas: Correlations with Clinicopathological Features , 2014, Tumori.

[7]  L. Horn,et al.  [New FIGO classification of ovarian, fallopian tube and primary peritoneal cancer]. , 2014, Der Pathologe.

[8]  Hanbyoul Cho,et al.  Overexpression of Glucose Transporter-1 (GLUT-1) Predicts Poor Prognosis in Epithelial Ovarian Cancer , 2013, Cancer investigation.

[9]  M. Jin,et al.  [Expression of glucose transporter protein 1 and desmin in reactive mesothelial hyperplasia and epithelioid malignant mesothelioma]. , 2013, Zhonghua bing li xue za zhi = Chinese journal of pathology.

[10]  W. Jung,et al.  The Expression of Glut-1, CAIX, and MCT4 in Mucinous Carcinoma , 2013, Journal of breast cancer.

[11]  V. Čapkun,et al.  P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas , 2013, Diagnostic Pathology.

[12]  D. Park,et al.  Prognostic Relevance of the Expression of CA IX, GLUT-1, and VEGF in Ovarian Epithelial Cancers , 2012, The Korean Journal of Pathology.

[13]  R. Rocha,et al.  CLINICS 2011;66(6):965-972 DOI:10.1590/S1807-59322011000600008 CLINICAL SCIENCE , 2022 .

[14]  A. Qazi,et al.  Expression of GLUT-1 in epithelial ovarian carcinoma: correlation with tumor cell proliferation, angiogenesis, survival and ability to predict optimal cytoreduction. , 2011, Gynecologic oncology.

[15]  C. Le Page,et al.  Predictive and Prognostic Protein Biomarkers in Epithelial Ovarian Cancer: Recommendation for Future Studies , 2010, Cancers.

[16]  Gong Yang,et al.  Ovarian cancer: pathology, biology, and disease models. , 2009, Frontiers in bioscience.

[17]  Kaoru Saito,et al.  Hypoxic status in ovarian serous and mucinous tumors: relationship between histological characteristics and HIF-1α/GLUT-1 expression , 2008, Archives of Gynecology and Obstetrics.

[18]  A. Mobasheri,et al.  Hypoxic Regulation of Glucose Transport, Anaerobic Metabolism and Angiogenesis in Cancer: Novel Pathways and Targets for Anticancer Therapeutics , 2007, Chemotherapy.

[19]  W. McCluggage,et al.  Immunohistochemical and functional biomarkers of value in female genital tract lesions. , 2006, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[20]  H. Kajiyama,et al.  Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival , 2006, British Journal of Cancer.

[21]  B. Melichar,et al.  Contribution of immunohistochemistry in prognostic assessment of epithelial ovarian carcinoma --review of the literature I. , 2006, Acta medica.

[22]  You-ji Feng,et al.  [Expression of glucose transporter-1 and its correlation with basic fibroblast growth factor and proliferating cell nuclear antigen in epithelial ovarian neoplasm]. , 2005, Zhonghua fu chan ke za zhi.

[23]  T. Manabe,et al.  [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. , 2005, Neoplasia.

[24]  D. Charnock-Jones,et al.  Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma , 2003, British Journal of Cancer.

[25]  D. Burstein,et al.  Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epithelia , 2002, Cancer.

[26]  G. Owen,et al.  Glucose transporters: expression, regulation and cancer. , 2002, Biological research.

[27]  E. Venkatraman,et al.  Identification of prognostic factors in advanced epithelial ovarian carcinoma. , 2001, Gynecologic oncology.

[28]  R. Angioli,et al.  GLUT‐1 expression in ovarian carcinoma , 2001, Cancer.

[29]  R. Airley,et al.  Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  C. Gomez-Fernandez,et al.  Expression of GLUT-1 glucose transporter in borderline and malignant epithelial tumors of the ovary. , 2000, Gynecologic oncology.

[31]  W. Rath,et al.  [Comparative studies on the biological significance of the marker for proliferation Ki-67-Antigen and PCNA in primary ovarian carcinoma]. , 2000, Zentralblatt fur Gynakologie.

[32]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[33]  M. Younes,et al.  Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. , 1996, Cancer research.

[34]  I. Schönborn,et al.  [Importance of PCNA proliferating fraction and histomorphologic prognostic factors for survival in breast cancer]. , 1993, Der Pathologe.

[35]  Johannes Gerdes,et al.  Monoclonal antibodies against recombinant parts of the Ki‐67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave‐processed formalin‐fixed paraffin sections , 1992, The Journal of pathology.